The MHRA has authorised Onswik (insulin efsitora alfa), a once-weekly basal insulin for adults with type 2 diabetes, following Phase 3 trials showing comparable HbA1c control.
Written By: Sravani Pamanji, PharmD
Reviewed By: Pharmacally Editorial Team
The UK Medicines and Healthcare products Regulatory Agency (MHRA) authorised Onswik (insulin efsitora alfa) on 13 October 2026 for treating type 2 diabetes mellitus in adults. Developed by Eli Lilly Nederland B.V., the long-acting basal insulin is administered once weekly, offering an alternative to daily basal insulin injections for eligible patients.
According to the MHRA, the treatment could reduce basal insulin injections from as many as 365 per year to 52 for some adults. The authorisation follows an assessment of clinical evidence showing that once-weekly insulin efsitora alfa achieved glycaemic control comparable to once-daily basal insulin treatments.
A New Approach to Basal Insulin
Type 2 diabetes is a chronic condition in which the body does not produce enough insulin or cannot use it effectively. Persistently elevated blood glucose can lead to serious complications if the condition is not adequately controlled.
Onswik contains insulin efsitora alfa, a long-acting basal insulin analogue designed for once-weekly administration. Basal insulin provides background insulin activity to help regulate blood glucose between meals and overnight.
By reducing injection frequency, the treatment may offer a practical alternative for adults who require basal insulin. However, fewer injections alone do not establish better treatment adherence, improved quality of life or superior clinical outcomes. Its suitability will depend on individual patient needs and the approved prescribing information.
How Insulin Efsitora Alfa Works
Insulin efsitora alfa regulates glucose metabolism through the established actions of insulin. It stimulates glucose uptake into peripheral tissues, particularly skeletal muscle and fat, while reducing glucose production by the liver. Insulin also inhibits the breakdown of fat and protein and promotes protein synthesis.
According to the European Medicines Agency (EMA), Onswik is available as a solution for injection in pre-filled pens at concentrations of 500 units/mL and 1,000 units/mL. Dosing and administration must follow the approved product information.
Phase 3 Trials Support Comparable Glycaemic Control
The clinical evidence comes from the QWINT 1–4 Phase 3 randomised, active-controlled trials. These studies evaluated once-weekly insulin efsitora alfa in adults with type 2 diabetes who were either new to insulin therapy or had previous insulin treatment experience.
The EMA reported that insulin efsitora alfa achieved reductions in glycated haemoglobin (HbA1c), a measure of average blood glucose, comparable to those achieved with once-daily basal insulin. Across the reported comparisons, differences in HbA1c versus comparator treatments ranged from −0.01 to −0.09 percentage points in insulin-naive and insulin-experienced populations.
These findings support the glucose-lowering efficacy of once-weekly insulin efsitora alfa relative to daily basal insulin in the studied populations. The small differences in HbA1c are consistent with comparable glycaemic outcomes, rather than evidence of superior glucose control.
The results establish a clinical basis for considering weekly basal insulin as an alternative administration schedule. They do not, by themselves, demonstrate that the treatment reduces long-term diabetes complications or improves adherence in routine clinical practice.
Hypoglycaemia Remains a Key Safety Consideration
Hypoglycaemia, or low blood glucose, was identified by both the MHRA and EMA as the most common adverse reaction reported with insulin efsitora alfa.
The MHRA will continue monitoring the medicine through its established safety-surveillance systems. Patients who suspect they are experiencing an adverse reaction should seek advice from a healthcare professional and report it through the Yellow Card scheme or the MHRA Yellow Card app.
The MHRA stated that the Summary of Product Characteristics and Patient Information Leaflet would be published on its Products website in due course. These documents will provide further information on warnings, precautions and appropriate use.
UK Regulatory Pathway
The MHRA granted marketing authorisation to Eli Lilly Nederland B.V. on 13 October 2026 through the ACCESS Procedure, a regulatory collaboration involving participating medicines agencies.
Earlier, on 25 June 2026, the EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorisation. This was a separate regulatory milestone from the subsequent UK authorisation.
The National Institute for Health and Care Excellence (NICE) has also published final draft guidance recommending insulin efsitora alfa for certain adults with type 2 diabetes. The recommendation was subject to MHRA licensing, which has now been granted. The final draft guidance should not be confused with final published NICE guidance.
What the Approval Means
Onswik introduces a once-weekly basal insulin option for adults with type 2 diabetes in the UK. Its principal distinction is the reduced injection frequency, while the QWINT Phase 3 findings support glycaemic control comparable to daily basal insulin in the studied populations.
The treatment’s place in clinical practice will depend on the approved prescribing information, individual patient suitability and the assessment of safety alongside glycaemic control. The authorisation expands the available approaches to basal insulin delivery, but does not establish that weekly administration is preferable for every patient.
References
MHRA. MHRA authorises Onswik (insulin efsitora alfa) for adults with type 2 diabetes. 13 October 2026.
European Medicines Agency. Onswik: European Public Assessment Report.
NICE. Insulin efsitora alfa for treating type 2 diabetes: appraisal information.
About the Writer
Sravani Pamanji is a PharmD (LinkedIn) professional with experience in scientific writing, medical literature review, drug profile preparation, and clinical case documentation. She has contributed to scientific publication and presented at the 74th Indian Pharmaceutical Congress. Her training includes ICH GCP E6(R3), scientific research, and medication safety. She is passionate about evidence-based medical communication and accurate dissemination of clinical and pharmaceutical information.